Effect of Centratherum anthelminticum seeds on Glycated hemoglobin, Cardiovascular disease risks and dyslipidemia in Type-2 diabetic patients in Karachi: A non-blind randomized controlled trial

• Published in: Pakistan journal of medical sciences 2025-01, Vol.41 (1), p.257-262
• Main Authors: Hina Akram Mudassir, Syed Muhammed Talha Arshad, Munazzah Naheed, Sadia Anwer
• Format: Article
• Language: English
• ISSN: 1682-024X; 1681-715X
• DOI: 10.12669/pjms.41.1.8496

Objective: To explore the effect of Centratherum antheminticum seeds powder {CapCASP 500 mg} capsule in diabetes Type-2 (T2DM) patients in Karachi. Methods: A randomized selection of 40 T2DM patients from Sindh Government Hospital New Karachi with their consents was done for a non-blinded controlled trial from October to December 2019 and divided into PGroup (Positive Control, metformin 500 mg) & TGroup (Test, CapCASP + was also included, using the same dosage of CapCASP on twenty healthy volunteers. The data were analyzed using an online graph pad student’s t-test and a one-way ANOVA (SPSS version 24) metformin 500mg each). Both groups had (n = 20). CGroup (healthy control), was also included with twenty healthy volunteers with same dose of CapCASP. The biochemical tests (lipid profile, HbA1c, fasting blood glucose) of both groups were done in biochemistry lab Federal Urdu University of Arts, Science & Technology and results were analyzed by one-way ANOVA (SPSS version 24) and online graph pad student´s t-test. Results: CASP showed potent (in-vitro) anti-diabetic activity (72.81%) than standard acarbose (standard drug). Most of in-vivo parameters in TGroup showed significant improvements. Body weight (p